Satellos' new Duchenne study endpoint; Amgen's Repatha cuts heart attack risk
Plus, news about MetaVia, Agios Pharmaceuticals and Inovio. Satellos Bioscience changes Duchenne study primary endpoint: The company is studying a small-molecule drug called forazapadin aimed at helping muscle repair and growth in boys with Duchenne ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.